Skip to main content
SpringerLink
Log in

Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?

  • Heart Failure (MR Mehra and E Joyce, Section Editors)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Despite the rising prevalence of HF, new evidence-based novel therapies for patients with worsening HF remain lacking, e.g., safe inotropic therapies. Traditional inotropes increase contractility by altering intracellular calcium flux, a pathway that may be responsible for the multitude of adverse effects associated with current options. Omecamtiv mecarbil, a direct myosin activator, increases contractility through a distinct pathway by increasing the proportion of myosin heads that are bound to actin in a high-affinity state. Phase II clinical trials in patients with chronic HF with this agent seem promising. A phase III trial investigating this therapy has not yet been pursued to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.

    Article  PubMed  Google Scholar 

  2. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344–50.

    Article  CAS  PubMed  Google Scholar 

  3. Chen J, Normand SL, Wang Y, et al. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011;306(15):1669–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mozaffarian D. Heart Disease and Stroke Statistics—2015 update: a report from the American Heart Association (vol 131, pg e29, 2015). Circulation. 2015;131(24):E535-E.

    Article  Google Scholar 

  5. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart failure. 2013;6(3):606–19.

    Article  CAS  PubMed  Google Scholar 

  6. Kojima S, Wu ST, Parmley WW, et al. Relationship between intracellular calcium and oxygen consumption: effects of perfusion pressure, extracellular calcium, dobutamine, and nifedipine. Am Heart J. 1994;127(2):386–91.

    Article  CAS  PubMed  Google Scholar 

  7. Ito M, Tanaka T, Saitoh M, et al. Selective inhibition of cyclic AMP phosphodiesterase from various human tissues by milrinone, a potent cardiac bipyridine. Biochem Pharmacol. 1988;37(10):2041–4.

    Article  CAS  PubMed  Google Scholar 

  8. Colucci WS. Cardiovascular effects of milrinone. Am Heart J. 1991;121(6 Pt 2):1945–7.

    Article  CAS  PubMed  Google Scholar 

  9. Tsien RW, Bean BP, Hess P, et al. Mechanisms of calcium channel modulation by beta-adrenergic agents and dihydropyridine calcium agonists. J Mol Cell Cardiol. 1986;18(7):691–710.

    Article  CAS  PubMed  Google Scholar 

  10. Hasenfuss G, Pieske B, Castell M, et al. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98(20):2141–7.

    Article  CAS  PubMed  Google Scholar 

  11. Massie B, Bourassa M, DiBianco R, et al. Long-term oral administration of amrinone for congestive heart failure: lack of efficacy in a multicenter controlled trial. Circulation. 1985;71(5):963–71.

    Article  CAS  PubMed  Google Scholar 

  12. Digitalis Investigation G. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336(8):525–33.

    Article  Google Scholar 

  13. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther. 1998;63(6):682–5.

    Article  CAS  PubMed  Google Scholar 

  14. Bader FM, Gilbert EM, Mehta NA, et al. Double-blind placebo-controlled comparison of enoximone and dobutamine infusions in patients with moderate to severe chronic heart failure. Congest Heart Fail. 2010;16(6):265–70.

    Article  CAS  PubMed  Google Scholar 

  15. Packer M, Colucci W, Fisher L, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103–11.

    Article  PubMed  Google Scholar 

  16. Cuffe MS, Califf RM, Adams Jr KF, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA. 2002;287(12):1541–7.

    Article  CAS  PubMed  Google Scholar 

  17. Kalogeropoulos AP, Marti CN, Georgiopoulou VV, et al. Inotrope use and outcomes among patients hospitalized for heart failure: impact of systolic blood pressure, cardiac index, and etiology. J Card Fail. 2014;20(8):593–601.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation. 2003;108(4):492–7.

    Article  PubMed  Google Scholar 

  19. Malik FI, Morgan BP. Cardiac myosin activation part 1: from concept to clinic. J Mol Cell Cardiol. 2011;51(4):454–61.

    Article  CAS  PubMed  Google Scholar 

  20. Lodish HF. Molecular cell biology. 4th ed. New York: W. H. Freeman; 2000. 2000. xxxvi, 1084, G-17, I-36 p. p.

    Google Scholar 

  21. Malik FI, Hartman JJ, Elias KA, et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011;331(6023):1439–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Shen YT, Malik FI, Zhao X, et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circ Heart Failure. 2010;3(4):522–7.

    Article  PubMed  Google Scholar 

  23. Teerlink JR, Clarke CP, Saikali KG, et al. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet. 2011;378(9792):667–75.

    Article  CAS  PubMed  Google Scholar 

  24. Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet. 2011;378(9792):676–83.

    Article  CAS  PubMed  Google Scholar 

  25. Greenberg BH, Chou W, Saikali KG, et al. Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina. JACC Heart Fail. 2015;3(1):22–9. The possible ischemia signal from earlier OM studies was explored in this elegantly designed randomized trial.

    Article  PubMed  Google Scholar 

  26. Late-Breaking Clinical Trial Abstracts. Circulation. 2015;132(23):2267–85. The findings of COSMIC-AHF have not yet been formally published but were discussed as a Late-Breaking Clinical Trial at the Scientific Sessions of the American Heart Association in November of 2015 (see Reference 27).

  27. Teerlink JR. Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): final results from a double-blind, randomized, placebo-controlled, multicenter study. presentation at american heart association scientific sessions: late-breaking clinical trials; 2015; Orlando, Florida. http://www.amgen.com/media/news-releases/2015/11/amgen-and-cytokinetics-announce-late-breaking-presentation-of-cosmic-hf-trial-at-aha-scientific-sessions-2015/.

  28. Teerlink JR, Felker GM, McMurray JJ, et al. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016;67(12):1444–55. While the primary dyspnea endpoint was not met in ATOMIC-AHF, this study proved to be hypothesis generating given the dyspnea improvement seen in the highest dose OM cohort.

    Article  CAS  PubMed  Google Scholar 

  29. de Antonio M, Lupon J, Galan A, et al. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. Am Heart J. 2012;163(5):821–8.

    Article  PubMed  Google Scholar 

  30. Wang TJ. Significance of circulating troponins in heart failure: if these walls could talk. Circulation. 2007;116(11):1217–20.

    Article  PubMed  Google Scholar 

  31. Gao WD, Atar D, Liu Y, et al. Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res. 1997;80(3):393–9.

    CAS  PubMed  Google Scholar 

  32. Schwartz P, Piper HM, Spahr R, et al. Ultrastructure of cultured adult myocardial cells during anoxia and reoxygenation. Am J Pathol. 1984;115(3):349–61.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Hessel MH, Atsma DE, van der Valk EJ, et al. Release of cardiac troponin I from viable cardiomyocytes is mediated by integrin stimulation. Pflugers Arch. 2008;455(6):979–86.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Stony Brook University School of Medicine, Stony Brook, NY, USA

    Danyaal S. Moin, Julia Sackheim, Carine E. Hamo & Javed Butler

  2. Health Sciences Center, Stony Brook University Medical Center, T16-080, Stony Brook, NY, 11794, USA

    Javed Butler

Authors
  1. Danyaal S. Moin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julia Sackheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Carine E. Hamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Javed Butler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Javed Butler.

Ethics declarations

Conflict of Interest

Danyaal S. Moin, Julia Sackheim, and Carine E. Hamo declare that they have no conflict of interest. Javed Butler reports receiving research support from the National Institutes of Health, and European Union, and serves as a consultant to Novartis, Amgen, Bayer, Janssen, Cardiocell, Stealth Peptide, Relypsa, Trevena, Z Pharma, Merck, Boehringer Ingelheim, and Zensun.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Heart Failure

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moin, D.S., Sackheim, J., Hamo, C.E. et al. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?. Curr Cardiol Rep 18, 100 (2016). https://doi.org/10.1007/s11886-016-0778-x

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-016-0778-x

Keywords

Search

Navigation